Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 776 • 2013 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Modifies Chromatin Landscape and Amplifies Inflammatory Responses To Subsequent Stimuli In Synovial Fibroblasts
Angela Lee¹, Lionel B. Ivashkiv² and George D. Kalliolias¹, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Fibroblast-like synoviocytes (FLS) cross-talk with macrophages (Mf) during the course of rheumatoid arthritis (RA). Our group has shown that TNFa, primarily Mf-derived within synovium,…
Abstract Number: 166 • 2013 ACR/ARHP Annual Meeting
The Potential Role Of Protein Tyrosine Phosphatase Receptor D (PTPRD) Gene Copy Number Variation In Susceptibility To Rheumatoid Arthritis
Su Jin Yoo¹, Mi Kyoung Lim², Donghyuk Sheen³, In Seol Yoo⁴, Jinhyun Kim⁵, Seong Wook Kang⁴ and Seung-Cheol Shim⁶, ¹Rheumatology, Chungnam National University School of Medicine, Daejeon, South Korea, ²Medicine, Eulji University Hospital, Daejeon, South Korea, ³Rheumatology, Eulji University Hospital, Daejeon, South Korea, ⁴Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁵Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁶Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea
Background/Purpose: Since it is important to explore genetic variations associated with rheumatoid arthritis (RA), genome-wide association studies (GWAS) have led to the identification of RA…
Abstract Number: 2345 • 2013 ACR/ARHP Annual Meeting
Long-Term Targeted Safety Event Rates In RA Patients Following Initiation Of Rituximab: Interim Analysis From Sunstone Registry
Kenneth G. Saag¹, Kevin L. Winthrop², Kimberly Alexander³, Steven Francom⁴ and Daniel Furst⁵, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³Epidemiology, Genentech, Inc., South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA, ⁵Rheumatology, UCLA, Los Angeles, CA
Background/Purpose: Rituximab (RTX) is used for the treatment of rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti-TNF therapy (TNF-IR). Long-term safety…
Abstract Number: 1471 • 2013 ACR/ARHP Annual Meeting
Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Maria E. Suarez-Almazor² and Mahesh Bavineni³, ¹General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Internal Medicine, Louisiana State University Lafayette, Lafayette, LA
Background/Purpose: Tofacitinib was developed as a small molecule inhibitor of the Janus kinase (JAK) pathways that are central to the maintenance of the inflammatory state…
Abstract Number: 457 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamic Effect Of Intravenous Golimumab By Messenger Ribonucleic Acid Expression Profiling
Yauheniya Cherkas, Carrie Brodmerkel, Mark Curran and Sarah Lamberth, Janssen Research & Development, LLC., Spring House, PA

Background/Purpose: RA is a chronic systemic autoimmune disease resulting in joint inflammation and damage. Despite the current therapies available, only a small percentage of RA…
Abstract Number: 2152 • 2012 ACR/ARHP Annual Meeting
Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-α Production
Jun Li¹, Hui-Chen Hsu², PingAr Yang¹, Qi Wu¹, David M. Spalding³, W. Winn Chatham⁴, Robert P. Kimberly⁵, S. Louis Bridges Jr.⁶ and John D. Mountz⁷, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Clinical Immunology & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁷Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL
Background/Purpose: Fucosylation, catalyzed by fucosyltransferases (Futs), is an important glycosylation process involved in inflammation, cell death, and differentiation. We have observed an extremely high positive correlation…
Abstract Number: 1584 • 2012 ACR/ARHP Annual Meeting
Validity of the Nurses Health Study II Physical Activity Questionnaire (NHSPAQ) in Estimating Physical Activity in Adults with Rheumatoid Arthritis (RA)
Maura D. Iversen¹, Thomas Quinn² and Michelle A. Frits³, ¹Department of Physical Therapy, Movement & Rehabilitation Sciences, Northeastern University, Boston, MA, ²Biology, Northeastern University, Boston, MA, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: An accurate assessment of physical activity (PA) is critical to manage rheumatoid arthritis (RA). Accelerometry is an objective measure of PA but is not…
Abstract Number: 652 • 2012 ACR/ARHP Annual Meeting
Serum Rituximab Levels and Efficiency of B-Cell Depletion: Differences Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Venkat Reddy¹, Sara Croca², Delia Gerona³, Inmaculada De La Torre Ortega³, David A. Isenberg⁴, Maria Leandro² and Geraldine Cambridge⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁴Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in rituximab-induced B-cell depletion (BCD) occurs in a significant number of patients with Systemic Lupus Erythematosus (SLE) and to a lesser extent in…
Abstract Number: 352 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis
Charlotte Hua¹, Thomas Barnetche², Bernard Combe³ and Jacques Morel⁴, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact…
Abstract Number: 2665 • 2012 ACR/ARHP Annual Meeting
Metabolic Reprogramming of Autoimmune T Cells in Rheumatoid Arthritis
Zhen Yang¹, Hiroshi Fujii², Shalini Mohan¹, Jorg J. Goronzy¹ and Cornelia M. Weyand³, ¹Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ³Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In RA, autoimmunity precedes clinical symptoms by a decade and persists unabated even when downstream inflammation is well controlled; exposing lymphocytes to chronic stimulation…
Abstract Number: 2129 • 2012 ACR/ARHP Annual Meeting
Dickkopf-1 Is Increased in Rheumatoid Arthritis of Recent Onset and Might Be a New Biomarker of Structural Progression. Data From the Espoir Cohort
Raphaèle Seror¹, Stephan Pavy², Thierry Schaeverbeke³, Alain Saraux⁴, Xavier Mariette⁵ and Corinne Miceli-Richard¹, ¹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²Hopital Bicetre, Paris, France, ³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁴Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ⁵Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Dickkopf-1 (DKK-1) is an inhibitory protein of the Wnt signalling pathway that could be involved in subchondral bone erosions occurring in rheumatoid arthritis (RA).…
Abstract Number: 1338 • 2012 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation
M.M. Herenius¹, A.S.F. Oliveira¹, C.A. Wijbrandts¹, D. Gerlag¹, Paul P. Tak² and Maria C. Lebre³, ¹Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Chemerin is a specific chemoattractant for macrophages and dendritic cells (DC). In addition, it can rapidly stimulate macrophage adhesion to extracellular matrix proteins and…
Abstract Number: 490 • 2012 ACR/ARHP Annual Meeting
12- and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Douglas E. Schlichting², Kimberly L. Sterling³, Edward Keystone⁴, Peter Taylor⁵, Mark C. Genovese⁶, Louise Johnson⁷, Juan C. Rizo Rodriguez⁸, Chin H. Lee² and Carol L. Gaich³, ¹Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada, ⁵Kennedy Institute of Rheumatology, London, United Kingdom, ⁶Division of Rheumatology, Stanford University, Palo Alto, CA, ⁷PharmaNet/i3, Eden Prairie, MN, ⁸Clinical Investigation, Centro de Alta Especialidad en Reumatología e Investigación del Potosí, San Luis Potosi, San Luis Potosi, Mexico
Background/Purpose: Baricitinib (formerly, LY3009104/INCB028050) is a novel, oral inhibitor of the JAK1 and JAK2 in the JAK-STAT pathway known to be of importance in the…
Abstract Number: 345 • 2012 ACR/ARHP Annual Meeting
Predictive Software-Based Mathematical Modeling: A Novel Approach to Development of Oral Therapies for Rheumatoid Arthritis – Validation in a Murine Collagen Induced Arthritis Model
Gurkirpal Singh¹, Robinson Vidva², Prashant Nair², Saumya Radhakrishnan², Pradeep Fernandes², Taher Abbasi², Canio Refino³, Jay Dela Cruz³ and Shireen Vali², ¹Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA, ²CellWorks Group, Saratoga, CA, ³InTouch Bio, Alameda, CA
Background/Purpose: Rheumatoid Arthritis (RA) involves complex interactions of multiple cell systems, cytokines and mediators, and interlinked signaling. While molecularly-targeted therapies manipulate specific interactions, it is…
Abstract Number: 2101 • 2012 ACR/ARHP Annual Meeting
How Much Can Patient Reported Outcomes Improve Among Rheumatoid Arthritis Patients Who Have a Clinical Response to Biologic Therapy but Have Not Attained Low Disease Activity?
Jeffrey R. Curtis¹, Ying Shan, Jie Zhang¹, Jeffrey D. Greenberg³ and George W. Reed⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²New York Hospital for Joint Disease, New York, NY, ³University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Current treat-to-target (T2T) recommendations suggest that rheumatoid arthritis (RA) patients should strive for remission or low disease activity (LDA) as a goal. Treatment changes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].